Dear Editor, A 23-year-old man with unremarkable history was admitted in our department because of pancytopenia and prolonged bleeding after teeth surgery 1 week earlier. He was taking no medication, and there was no evidence of recent acute viral syndrome. His blood count showed Hb, 8.2 g/dl; white blood cell count, 1.9×10 9 /l (44% atypical granular blasts); and platelet count, 49 × 10 9 /l. Coagulation tests were consistent with fibrinogenolysis (fibrinogen, 71 mg/dl; Ddimer, 1345 ng/ml; prothrombin time, 48%; international normalized ratio, 1.56; activated partial thromboplastin time, 33 s). Based on peripheral and bone marrow picture, immunophenotype, and detection of PML-RAR alpha rearrangement associated with t(15;17) (fluorescent in situ hybridization), the diagnosis of hypergranular acute promyelocitic leukemia was made. Induction treatment with all-trans retinoic acid and idarubicin schedule [all-trans retinoic acid (ATRA) 45 mg/m 2 per day os, days 1-30; idarubicin, 12 mg/m 2 per day iv, days 2, 4, 6, 8] was started. Supportive therapy with low-dose prednisone, tranexamic acid, and plasma transfusion was also initiated.
On day 6 of ATRA treatment, echocardiography showed left ventricular enlargement (end-diastolic volume 160 ml, normal range: 67-155 ml; indexed end-diastolic volume 90 ml/m 2 , normal range 35-75 ml/m 2 ) with diffuse hypokinesia and reduced ejection fraction (45%, normal range: ≥55%; figure, left panels). Electrocardiographic findings were within normal limits. The patient became febrile and reported asthenia (NYHA II), dyspnea, and diffuse muscular pain. A pleural effusion and weight increase (+6 kg) were also observed. Repeated measurements of troponine I, myoglobin, and CK-MB were within the normal ranges, whereas brain natriuretic peptide was elevated (321 pg/ml, normal range: <100 pg/ml). White blood cell count showed leukocytosis (17.1×10 9 /l) with atypical granular blasts. A diagnosis of ATRA syndrome was made. Treatment with diuretics and full-dose prednisone was started while ATRA was discontinued. In the following days, fever and muscular pain disappeared. Three months later, echocardiography showed reduction of left ventricular size (end-diastolic volume, 124 ml; indexed end-diastolic volume, 72 ml/m 2 ) with normalization of ejection fraction (62%; figure, right panels) .
The pathogenesis of myocarditis in patients under ATRA treatment depends on complex interaction between extravasation of acute promyelocitic leukemia cells, leukocyte infiltration, endothelial injury, and cytokine release, leading to myocardial cell lysis and release of cardiac biochemical markers into the blood [1] . To our knowledge, only three cases of ATRA-induced myocarditis-all with electrocardiographic modifications and increase in myocardial necrosis indices-have been reported [1, 2] . In this case, clinical and echocardiographic evidence of left ventricular systolic dysfunction occurred without electrocardiographic changes and despite normality of myocardial biomarkers. Although causal relation between ATRA administration and cardiac dysfunction cannot be directly demonstrated, we found no evidence of other conditions associated with increased risk of myocarditis. Based on the absence of clinical or echocardiographic signs of concomitant endocarditis, a potential role of recent dental surgery also seems unlikely. Moreover, based on the Naranjo scale [3] -an objective algorithm for assessing the probability of adverse drug reactions-the causal relation between ATRA administration and cardiac dysfunction was categorized as probable. This suggests the intriguing hypothesis that ATRA cardiac toxicity may lead to myocardial damage and reversible dysfunction even in the absence of significant myocytolysis.
